Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Rheumatic Heart Disease IV: Nursing Management

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...

Rheumatic Heart Disease I: Introduction

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses.

CADTH technology overviews·2012

Same author

Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses.

CADTH technology overviews·2012

Same authorSame journal

Continuous erythropoietin receptor activator (Mircera) for renal anemia.

Issues in emerging health technologies·2008

Same author

Chondroitin sulfate for interstitial cystitis.

Issues in emerging health technologies·2006

Same author

CYP450 genotyping for determining drug metabolizer status.

Issues in emerging health technologies·2006

Same author

Surveillance mammography after treatment of primary breast cancer: a systematic review.

Breast (Edinburgh, Scotland)·2004

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Rituximab for rheumatoid arthritis.

E Palylyk-Colwell, L McGahan

Issues in Emerging Health Technologies

|October 4, 2006

Summary

Rituximab (RTX) combined with methotrexate (MTX) significantly improves clinical outcomes for rheumatoid arthritis (RA) patients unresponsive to other treatments. Further research is needed on optimal dosing and long-term effects of this RA therapy.

Area of Science:

Immunology
Rheumatology
Pharmacology

Background:

Rheumatoid arthritis (RA) pathogenesis involves CD20+ B-cells.
Rituximab (RTX) is a monoclonal antibody targeting CD20+ B-cells.

Purpose of the Study:

To evaluate the efficacy of RTX in combination with methotrexate (MTX) for rheumatoid arthritis patients.
To compare RTX + MTX therapy against MTX monotherapy in RA patients with inadequate response to standard treatments.

Main Methods:

Clinical trial comparing RTX + MTX versus MTX alone.
Assessment of statistically significant clinical improvements in RA patients.

Main Results:

The combination of RTX and MTX demonstrated statistically significant clinical improvements compared to MTX alone.

Related Experiment Videos

Last Updated: Jul 19, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

This combination therapy is effective for RA patients with an inadequate response to standard therapies.

Conclusions:

Rituximab (RTX) plus methotrexate (MTX) offers a viable treatment option for moderate to severe active rheumatoid arthritis (RA).
Further investigation is required for optimal dosing, duration, long-term safety, and treatment algorithm placement of RTX in RA management.
Health Canada has approved RTX + MTX for specific RA patient populations, including those intolerant to TNF inhibitors.